<DOC>
	<DOC>NCT02954575</DOC>
	<brief_summary>The purpose of this study is to obtain additional data on the safety and efficacy of Wilate in PTPs with hemophilia A with at least 150 previous exposure days (EDs) to a FVIII concentrate who undergo prophylactic treatment with Wilate for 6 months and at least 50 EDs, thus supplementing the existing database to obtain approval of Wilate for the indication hemophilia A in the USA.</brief_summary>
	<brief_title>Clinical Study to Investigate the PK, Efficacy, and Safety of Wilate in Patients With Severe Hemophilia A</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>1. Severe hemophilia A (&lt;1% FVIII:C) according to medical history 2. Male patients aged ≥12 years 3. Previous treatment with a FVIII concentrate for at least 150 exposure days (EDs) 4. Immunocompetence (CD4+ count &gt;200/µL) 5. Good documentation of the historical bleeding rate (at least for the 6 months preceding study start) 6. Voluntarily given, fully informed written and signed consent obtained by the patient (or parent/legal guardian in case of adolescents) before any studyrelated procedures are conducted 1. Any coagulation disorders other than hemophilia A 2. History of FVIII inhibitor activity (≥0.6 BU) or detectable FVIII inhibitory antibodies (≥0.6 BU using the Nijmegen modification of the Bethesda assay) at screening, as determined by the central laboratory 3. Severe liver or kidney diseases (alanine aminotransferase [ALAT] and aspartate transaminase [ASAT] levels &gt;5 times of upper limit of normal, creatinine&gt;120 µmol/L) 4. Patients receiving or scheduled to receive immunomodulating drugs (other than antiretroviral chemotherapy) such as alphainterferon, prednisone (equivalent to &gt;10 mg/day), or similar drugs 5. Treatment with any investigational medicinal product in another interventional clinical study currently or within 4 weeks before enrollment</criteria>
	<gender>Male</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>